Vivos Inc
radiogel.comVivos Inc (OTC: RDGL) is a radiopharmaceutical company that develops and sells yttrium-90 (Y-90) phosphate particle therapies for cancer treatment in both humans and animals. Revenue comes from product sales of RadioGel and IsoPet doses to clinics, a clinic certification licensing program introduced in 2024, and direct sales of hydrogel vials used in treatments. The company operates at an early commercial stage, with its human therapy product (RadioGel) still pending FDA regulatory clearance as of the 10-K filed March 31, 2026, while its veterinary product (IsoPet) is being commercialized. The company reported net losses of $3,066,017 for the year ended December 31, 2025, and $2,910,448 for the year ended December 31, 2024, with negative operating cash flows of $2,057,743 in FY2025. Leadership includes CEO Michael K. Korenko, Interim CFO Michael Pollack, and Chairman Carlton M. Cadwell. The company funds operations primarily through equity raises, including a Regulation A+ offering that raised $1,553,000 in March 2026.
Products & Services
RadioGel (Y-90 phosphate particle brachytherapy device for human cancer treatment, FDA Breakthrough Device designation granted December 2023, IDE resubmission pending as of Q1 2026); IsoPet (Y-90 phosphate particle therapy for veterinary cancer treatment, commercially active, reported 1,200% year-over-year increase in administered therapies from 2024 to 2025); PrecisionGel hydrogel vials used as the delivery medium for both therapies.
Revenue Model
Transactional product sales of Y-90 RadioGel and IsoPet doses to veterinary clinics and (pending regulatory approval) human therapy clinics; clinic certification licensing fees recognized upon certification completion (introduced in 2024); and direct sales of hydrogel vials to select customers at a pricing discount from the manufacturer.
Customers & Markets
Veterinary clinics treating animal cancer patients (IsoPet division, primary active revenue source as of FY2025); human oncology clinics (RadioGel, pending FDA IDE approval and clearance); two unnamed customers received direct hydrogel vial sales as of FY2024 filing.
Geographic Exposure
Domestic operations based in the United States; international manufacturing discussions underway in India through VSIL; human therapy data generation ongoing in India as of the 10-K filed March 31, 2026.
Financial Snapshot
Loading...
